Fandom

VroniPlag Wiki

Quelle:Iam/Kamrava et al 2009

< Quelle:Iam

31.359Seiten in
diesem Wiki
Seite hinzufügen
Diskussion0

Störung durch Adblocker erkannt!


Wikia ist eine gebührenfreie Seite, die sich durch Werbung finanziert. Benutzer, die Adblocker einsetzen, haben eine modifizierte Ansicht der Seite.

Wikia ist nicht verfügbar, wenn du weitere Modifikationen in dem Adblocker-Programm gemacht hast. Wenn du sie entfernst, dann wird die Seite ohne Probleme geladen.

Angaben zur Quelle [Bearbeiten]

Autor     Mitchell Kamrava, Michael B. Bernstein, Kevin Camphausen, James W. Hodge
Titel    Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?
Zeitschrift    Molecular BioSystems
Herausgeber    The Royal Society of Chemistry
Datum    27. August 2009
Seiten    1262–1270
DOI    10.1039/b911313b
URL    http://pubs.rsc.org/en/content/pdf/article/2009/mb/b911313b

Literaturverz.   

yes
Fußnoten    yes
Fragmente    2


Fragmente der Quelle:
[1.] Iam/Fragment 012 18 - Diskussion
Zuletzt bearbeitet: 2014-03-12 19:43:41 Graf Isolan
BauernOpfer, Fragment, Gesichtet, Iam, Kamrava et al 2009, SMWFragment, Schutzlevel sysop

Typus
BauernOpfer
Bearbeiter
Hindemith
Gesichtet
Yes.png
Untersuchte Arbeit:
Seite: 12, Zeilen: 18-18
Quelle: Kamrava et al 2009
Seite(n): 1268, Zeilen: 1ff
12a diss Iam.png

Figure 6: The combined use of radiation, immunotherapy and angiogenesis inhibitors-by normalizing blood flow and lowering intratumoral pressure, angiogenesis inhibitors enable T cells to gain efficient access to the tumor, while increasing the necessary components for effective T-cell function at the tumor site. Furthermore, by reducing hypoxia, antiangiogenic agents allow for optimization of radiotherapy, thereby providing the immune system with a rich supply of tumor antigens while modulating tumor-cell phenotype for enhanced T-cell killing (adapted by Kamrava et al. 2009)


Kamrava M, Bernstein MB, Camphausen K, Hodge JW (2009) Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? Mol Biosyst 5:1262-1270

12a source Iam.png

Fig. 4 The combined use of radiation, immunotherapy, and angiogenesis inhibitors-by normalizing blood flow and lowering intratumoral pressure, angiogenesis inhibitors enable T cells to gain efficient access to the tumor, while increasing the necessary components for effective T-cell function at the tumor site. Furthermore, by reducing hypoxia, antiangiogenic agents allow for optimization of radiotherapy, thereby providing the immune system with a rich supply of tumor antigens while modulating tumor-cell phenotype for enhanced T-cell killing.

Anmerkungen

The source is given, but it is not clear to the reader that the image as well as the extensive caption have both been taken from it.

"adapted by Kamrava et al. 2009" should probably be "adopted from Kamrava et al. 2009"

Sichter
(Hindemith) Schumann

[2.] Iam/Fragment 074 02 - Diskussion
Zuletzt bearbeitet: 2014-03-12 19:43:47 Graf Isolan
Fragment, Gesichtet, Iam, Kamrava et al 2009, KomplettPlagiat, SMWFragment, Schutzlevel sysop

Typus
KomplettPlagiat
Bearbeiter
Hindemith
Gesichtet
Yes.png
Untersuchte Arbeit:
Seite: 74, Zeilen: 2-10
Quelle: Kamrava et al 2009
Seite(n): 1262, Zeilen: 9-17
With the advent of new cancer therapies in the last few years, the goals of reducing disease burden and improving quality of life are frequently achieved. Yet despite the advances seen with numerous monotherapies, a multimodality approach that targets different aspects of tumor biology may yield the greatest clinical benefit for patients with late-stage disease. Many such strategies have been employed with varying degrees of success. The addition of immunotherapy to standard-of-care radiation therapy has shown evidence of efficacy in some preclinical models and in the clinical setting. However, exploiting these two modalities safely and effectively remains an ongoing challenge. It is feasible that the addition of another therapeutic modality could further enhance the antitumor effects of these treatments. With the advent of new cancer therapies in the last few years, the goals of reducing disease burden and improving quality of life are frequently achieved. Yet despite the advances seen with numerous monotherapies, a multimodality approach that targets different aspects of tumor biology may yield the greatest clinical benefit for patients with late stage disease. Many such strategies have been employed with varying degrees of success. The addition of immunotherapy to standard-of-care radiation therapy has shown evidence of efficacy in some preclinical models and in the clinical setting. However, exploiting these two modalities safely and effectively remains an ongoing challenge. It is feasible that the addition of another therapeutic modality could further enhance the antitumor effects of these treatments.
Anmerkungen

The source is not mentioned.

Sichter
(Hindemith) Schumann

Auch bei Fandom

Zufälliges Wiki